MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
Rhea-AI Summary
MiNK Therapeutics (NASDAQ: INKT) announced its 2026 Annual Shareholders Meeting will be held virtually on June 17, 2026. The meeting starts at 9:30 a.m. ET, with registration beginning at 9:15 a.m. ET. A live webcast and replay will be available online.
Positive
- None.
Negative
- None.
News Market Reaction – INKT
On the day this news was published, INKT declined 0.08%, reflecting a mild negative market reaction. Argus tracked a peak move of +2.6% during that session. Argus tracked a trough of -5.4% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $51K from the company's valuation, bringing the market cap to $63.97M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 28 | Phase 2 trial start | Positive | +19.8% | First patient dosed in randomized Phase 2 agenT‑797 acute lung injury trial. |
| May 21 | AI oncology data | Positive | -0.6% | ASCO 2026 AI pathology analysis linking BOT+BAL response and survival in MSS CRC. |
| May 21 | Melanoma trial data | Positive | -0.6% | Phase 2 BOT+BAL melanoma results showing durable responses and survival data. |
| May 20 | Clinical data update | Positive | +3.8% | New clinical and translational agenT‑797 data in critically ill patient case. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent INKT-specific clinical updates (Phase 2 trial initiation and new agenT-797 data) saw positive price reactions, while positive Agenus trial data in related oncology indications coincided with negative moves in AGEN, indicating mixed responses across the broader platform ecosystem.
Over the past few weeks, MiNK highlighted progress for its allo‑iNKT program, including new agenT‑797 data reported on May 20, 2026 and first patient dosing in a randomized Phase 2 trial announced on May 28, 2026, both followed by positive price moves. Related Agenus oncology data on May 15 and May 21, 2026 were generally favorable clinically but saw negative price reactions. Against this backdrop, today’s annual meeting logistics are routine and non-clinical.
Key Terms
allogeneic medical
invariant natural killer t (inkt) cell therapies medical
nasdaq financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 17, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.
To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/INKT2026 and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is required for guests.
Webcast Information:
Date: Wednesday, June 17, 2026
Time: 9:30 a.m. ET
A live webcast and replay will be accessible from the Company's website at https://investor.minktherapeutics.com/events-and-presentations and at www.virtualshareholdermeeting.com/INKT2026.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic iNKT cell therapies for life-threatening conditions driven by immune dysfunction. The company's lead program, agenT-797, is being evaluated in acute lung injury and critical illness, with a pipeline that extends across immuno-oncology, transplant medicine, and other settings where dysregulated immunity is a driver of morbidity and mortality. MiNK believes that iNKT cell biology, because of its regulatory role across innate and adaptive immunity, may represent a foundational approach to immune restoration applicable across a broad range of conditions. For more information, visit www.minktherapeutics.com.
Contacts:
Investor Contact
917-362-1370
investor@minktherapeutics.com
Media Contact
781-674-4428
communications@minktherapeutics.com
